Aytu BioPharma, Inc. – NASDAQ:AYTU
Aytu BioPharma stock price today
$2.16
+0.64
+42.11%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Aytu BioPharma stock price monthly change
-45.52%
month
Aytu BioPharma stock price quarterly change
-45.52%
quarter
Aytu BioPharma stock price yearly change
-48.99%
year
Aytu BioPharma key metrics
Market Cap | 8.54M |
Enterprise value | 9.36M |
P/E | -0.05 |
EV/Sales | 0.08 |
EV/EBITDA | -0.13 |
Price/Sales | 0.06 |
Price/Book | 0.14 |
PEG ratio | N/A |
EPS | -23.85 |
Revenue | 98.90M |
EBITDA | -77K |
Income | -49.24M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -76.1% |
Oper. margin | -21.22% |
Gross margin | 59.53% |
EBIT margin | -21.22% |
EBITDA margin | -0.08% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAytu BioPharma stock price history
Aytu BioPharma stock forecast
Aytu BioPharma financial statements
| Jun 2022 | 27.44M | -38.05M | -138.65% |
|---|---|---|---|
| Mar 2023 | 22.73M | -5.84M | -25.7% |
| Jun 2023 | 30.73M | -2.45M | -7.99% |
| Mar 2024 | 17.99M | -2.88M | -16.05% |
| 2026 | 71.57M | 662K | 0.92% |
|---|---|---|---|
| 2027 | 117.7M | -1.06M | -0.91% |
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 141436000 | 95.61M | 67.61% |
|---|---|---|---|
| Mar 2023 | 147216000 | 106.30M | 72.21% |
| Jun 2023 | 136463000 | 97.10M | 71.16% |
| Mar 2024 | 128863000 | 98.08M | 76.12% |
| Jun 2022 | -7.09M | -41K | -1.11M |
|---|---|---|---|
| Mar 2023 | -2.90M | 1K | 2.58M |
| Jun 2023 | 9.36M | -155K | -5.40M |
| Mar 2024 | -254K | -45K | 530K |
Aytu BioPharma alternative data
| Aug 2023 | 164 |
|---|---|
| Sep 2023 | 164 |
| Oct 2023 | 164 |
| Nov 2023 | 150 |
| Dec 2023 | 150 |
| Jan 2024 | 150 |
| Feb 2024 | 150 |
| Mar 2024 | 150 |
| Apr 2024 | 150 |
| May 2024 | 150 |
| Jun 2024 | 150 |
| Jul 2024 | 150 |
Aytu BioPharma other data
12.19%
-8.94%
of AYTU is owned by hedge funds
3.61M
-1.96M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2022 | 312000 | 0 |
| Dec 2022 | 212371 | 0 |
| Jun 2023 | 26000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | PYSZCZYMUKA GREG officer: Chief Commercial Officer | Common Shares | 208 | N/A | N/A | ||
Option | PYSZCZYMUKA GREG officer: Chief Commercial Officer | Restricted Stock Units | 208 | N/A | N/A | ||
Option | PYSZCZYMUKA GREG officer: Chief Commercial Officer | Common Shares | 209 | N/A | N/A | ||
Option | PYSZCZYMUKA GREG officer: Chief Commercial Officer | Restricted Stock Units | 209 | N/A | N/A | ||
Option | PYSZCZYMUKA GREG officer: Chief Commercial Officer | Common Shares | 208 | N/A | N/A | ||
Option | PYSZCZYMUKA GREG officer: Chief Commercial Officer | Restricted Stock Units | 208 | N/A | N/A | ||
Option | PYSZCZYMUKA GREG officer: Chief Commerical Officer | Common Shares | 208 | N/A | N/A | ||
Option | PYSZCZYMUKA GREG officer: Chief Commerical Officer | Restricted Stock Units | 208 | N/A | N/A | ||
Purchase | PYSZCZYMUKA GREG officer: Chief Commerical Officer | Common Shares | 12,000 | $1.87 | $22,428 | ||
Purchase | DISBROW JOSHUA R. director, officer.. | Common Shares | 14,000 | $1.86 | $26,082 |
| Quarter | Transcript |
|---|---|
| Q3 2024 15 May 2024 | Q3 2024 Earnings Call Transcript |
| Q2 2024 14 Feb 2024 | Q2 2024 Earnings Call Transcript |
| Q1 2024 14 Nov 2023 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Sep 2023 | Q4 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Joshua R. Disbrow (1975) Chairman & Chief Executive Officer | $1,010,000 |
-
What's the price of Aytu BioPharma stock today?
One share of Aytu BioPharma stock can currently be purchased for approximately $2.16.
-
When is Aytu BioPharma's next earnings date?
Unfortunately, Aytu BioPharma's (AYTU) next earnings date is currently unknown.
-
Does Aytu BioPharma pay dividends?
No, Aytu BioPharma does not pay dividends.
-
How much money does Aytu BioPharma make?
Aytu BioPharma has a market capitalization of 8.54M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 24.58% to 81M US dollars.
-
What is Aytu BioPharma's stock symbol?
Aytu BioPharma, Inc. is traded on the NASDAQ under the ticker symbol "AYTU".
-
What is Aytu BioPharma's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Aytu BioPharma?
Shares of Aytu BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Aytu BioPharma's key executives?
Aytu BioPharma's management team includes the following people:
- Mr. Joshua R. Disbrow Chairman & Chief Executive Officer(age: 50, pay: $1,010,000)
-
How many employees does Aytu BioPharma have?
As Jul 2024, Aytu BioPharma employs 150 workers.
-
When Aytu BioPharma went public?
Aytu BioPharma, Inc. is publicly traded company for more then 17 years since IPO on 25 Sep 2008.
-
What is Aytu BioPharma's official website?
The official website for Aytu BioPharma is aytubio.com.
-
Where are Aytu BioPharma's headquarters?
Aytu BioPharma is headquartered at 373 Inverness Parkway, Englewood, CO.
-
How can i contact Aytu BioPharma?
Aytu BioPharma's mailing address is 373 Inverness Parkway, Englewood, CO and company can be reached via phone at +7 204376580.
Aytu BioPharma company profile:
Aytu BioPharma, Inc.
aytubio.comExchange:
NASDAQ
Full time employees:
102
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
373 Inverness Parkway
Englewood, CO 80112
Englewood, CO 80112
CIK: 0001385818
ISIN: US0547548588
CUSIP: 054754874
